LYCOS RETRIEVER 
Merck: Merck Kgaa
built 650 days ago
-- ChemBridge Research Laboratories, LLC (CRL) and Merck KGaA announced today successful accomplishment of their first collaboration project. In August 2003, CRL entered into a contract research agreement with Merck KGaA to provide CRL's discovery research capabilities to Merck. During the recent collaboration project CRL scientists synthesized multiple series of focused libraries under application of CRL's high-throughput medicinal chemistry platform to complement Merck's in-house lead finding efforts. Further details and financial terms were not disclosed.
Source:
Merck Serono (NYSE: SRA), a division of Merck KGaA, announced today the launch of its new website (http://www.merckserono.net). The fully redesigned website provides in-depth and up-to-date information on the Merck Serono division, in particular on its medical treatments, services and research & development activities, along with the latest news about the division.
Source:
(CSRwire) GENEVA & DARMSTADT, Germany--(BUSINESS WIRE)--April 19, 2007--Merck KGaA (FWB:MRK) (GER:MRK) announced today the conclusion of a ten-year partnership with WHO to control schistosomiasis in African schoolchildren. For this purpose, Merck will provide for free 200 million tablets Cesol(R) 600 (active ingredient praziquantel) with a value of approximately USD 80 million.
Source:
The terms of this new agreement provide that Merck KGaA will receive 50 percent of the profit/loss from sales in Japan, and ImClone Systems and BMS will each receive 25 percent. The sharing of profit/loss reflect the co- exclusive rights to ERBITUX in Japan, previously granted by ImClone Systems to Merck KGaA and Bristol-Myers Squibb. In addition to its percentage of profits, ImClone Systems will receive from Merck KGaA a royalty equal to 4.75 percent of total net sales in Japan.
Source:
EMD Serono, Inc., headquartered in Rockland, Massachusetts, is an affiliate of Merck KGaA in Darmstadt, Germany. EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection).
Source:
"This agreement further strengthens our partnership with ImClone Systems and Merck KGaA as we focus on maximizing the global potential of ERBITUX," said Lamberto Andreotti, Executive Vice President and Chief Operating Officer, Worldwide Pharmaceuticals, Bristol-Myers Squibb. "If approved in Japan, ERBITUX would be an important new addition to the treatments available to Japanese patients with EGFR-expressing metastatic colorectal cancer."
Source:
MORE ABOUT
Merck Kgaa